$EQ Cashflow Statement | Understand Stock

$EQ

$1.36 +$0.11 (8.8%) Close

$EQ Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Acquired in-process research and development
Depreciation
Loss on disposal of property and equipment
Stock-based compensation
Net unrealized (gain) loss on foreign currency transactions
Amortization of term loan discount and issuance costs
Amortization of investments, net
Deferred revenue
Changes in operating assets and liabilities:
Accounts receivable
Prepaid expenses and other current assets
Right-of-use assets, operating leases
Accounts payable
Accrued expenses
Operating lease liabilities
Right-of-use assets and lease liabilities, net

Net cash used in operating activities
Investing activities:
Purchases of property and equipment
Proceeds from disposal of property and equipment
Purchases of short-term investments
Maturities of short-term investments
Cash acquired in Bioniz acquisition
Net cash provided by investing activities

Financing activities:
Proceeds from registered direct offering, net of offering costs
Repayment of notes payable
Proceeds from a private placement of common stock and pre-funded warrants, net of issuance costs
Proceeds from exercise of stock options
Common stock repurchased
Proceeds from issuance of common stock under employee stock purchase plan
Follow-on Offering
Total proceeds from issuance of common stock under employee stock purchase plan

Proceeds from issuance of common stock
Net cash provided by financing activities

Effect of exchange rate changes on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Non-cash investing and financing activities:
Right-of-use assets obtained in exchange for lease obligations
Amounts included in accounts payable for purchases of property and equipment
ATM facility issuance costs reclassed from other current assets
Exercise Of Stock Options Issuance Costs In Accounts Payable

Supplemental cash flow information:
Cash paid for interest
Cash paid for income taxes
Fair value of Bioniz assets acquired
Issuance of common stock for Bioniz acquisition
Bioniz net liabilities assumed
Cash paid for income taxes, net of refunds

Comments